Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...
Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...
While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...
Firstsource Solutions Limited (NSE: FSL) (BSE: 532809), an RP-Sanjiv Goenka Group company, today announced its bold new direction?UnBPOtm?a transformative shift away from traditional outsourcing ...
BirdseyePost announces groundbreaking features in its autonomous marketing platform, enabling businesses of all sizes and sectors to rapidly launch targeted direct mail campaigns across North America.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback